Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 1/2001

01-01-2001 | Review Article

NSAID-Induced Nephrotoxicity from the Fetus to the Child

Authors: Laura Cuzzolin, Monica Dal Cerè, Dr Vassilios Fanos

Published in: Drug Safety | Issue 1/2001

Login to get access

Abstract

In this review we report data available from the literature on the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and the development of nephrotoxicity in the fetus, neonates and children. Up to the present day, several cases of severe and sometimes irreversible renal insufficiency have been described in neonates exposed to indomethacin prenatally or in the first days of life for treatment of patent ductus arteriosus (PDA). Until now, very few studies have been carried out on alternative treatments for PDA in preterm infants; ibuprofen has been shown to be as effective as indomethacin in closing the ductus in this patient group without affecting renal function. In children, NSAID-induced renal failure is a rare event and is usually reversible after discontinuation of the drug. However, caution should be taken when NSAIDs are administered to individuals with preexisting renal problems or with other potentially nephrotoxic drugs. In these situations, new approaches such as cyclo-oxygenase-2 selective inhibitors or prostanoid receptor selective antagonists could lead to alternative therapies for use in paediatrics.
Literature
1.
Kennedy L. NSAIDs and their effect on renal function. Pediatr Adolesc Med Alert 1999; 1(6): 41–8
2.
Garella S. Drug-induced renal disease. Hosp Pract 1993; 15: 129–40
3.
Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984; 310: 563–72PubMedCrossRef
4.
Murray MD, Brater DC. Adverse effects of nonsteroidal antiinflammatory drugs on renal function. Ann Intern Med 1990; 112: 559–60PubMed
5.
Dubose TD. Grand round: nephrotoxicity of non-steroidal antiinflammatory drugs. Lancet 1994; 344: 515–8CrossRef
6.
7.
Bennett W, Henrich W, Stoff JS. The renal effects of nonsteroidal antiinflammatory drugs. Summary and recommendations. Am J Kidney Dis 1996; 26: S56–62CrossRef
8.
Smith W. Prostanoid biosynthesis and mechanism of action.Am J Physiol 1992; 263: F181–91PubMed
9.
Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties and functions. Physiol Rev 1999; 79: 1193–226PubMed
10.
Palmer BF. Renal complications associated with the use of nonsteroidal anti-inflammatory agents. J Invest Med 1995; 43: 516–33
11.
Kaplan BS, Restaino I, Raval DS, et al. Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr Nephrol 1994; 8(6): 700–4PubMedCrossRef
12.
Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997; 49: 15–9
13.
Guan Y, Chang M, Cho W, et al. Cloning, expression and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol 1997; 273: F18–26PubMed
14.
Kömhoff M, Gröne H, Klein T, et al. Localization of cyclooxygenase-1 and −2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997; 272: F460–8PubMed
15.
Slater D, Dennes W, Sawdy R, et al. Expression of cyclooxygenase types-1 and −2 in human fetalmembranes throughout pregnancy. J Mol Endocrinol 1999; 22: 125–30PubMedCrossRef
16.
Sawdy R, Slater D, Fisk N, et al. Use of a cyclo-oxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm delivery. Lancet 1997; 350: 265–6PubMedCrossRef
17.
Guerguerian AM, Hardy P, Bhattacharya M, et al. Expression of cyclooxygenases in ductus arteriosus of fetal and newborn pigs. Am J Obstet Gynecol 1998; 179: 1618–26PubMedCrossRef
18.
Clyman RI, Chan CY, Mauray F, et al. Permanent anatomic closure of the ductus arteriosus in newborn baboons: the roles of postnatal constriction, hypoxia and gestation. Pediatr Res 1999; 45: 19–29PubMedCrossRef
19.
Clyman RI, Hardy P, Waleh N, et al. Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus. Am J Physiol 1999; 276: R913–21PubMed
20.
Breyer MD, Breyer RM. Prostaglandin receptors: their role in regulating renal function. Curr Opin Nephrol Hypertens 2000; 9: 23–9PubMedCrossRef
21.
Boye Y, Stocco R, Sawyer N, et al. Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol 1997; 340: 227–41CrossRef
22.
Ishibashi R, Tanaka I, Kotani M, et al. Roles of prostaglandin E receptors in mesangial cells under high-glucose conditions. Kidney Int 1999; 56: 589–600PubMedCrossRef
23.
Regan JW, Bailey TJ, Pepperl DJ, et al. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol Pharmacol 1994; 46: 213–20PubMed
24.
Coleman RA, Smith WL, Narumiya S. International union of pharmacology classification of prostanoid receptors: properties, distribution and structure of the receptors and their subtypes. Pharmacol Rev 1994; 46: 205–29PubMed
25.
Segi E, Sugimoto Y, Yamasaki A, et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun 1998; 246: 7–12PubMedCrossRef
26.
27.
Bugge JF, Stokke ES, Vikse A, et al. Stimulation of renin release by PGE2 and PGI2 infusion in the dog: enhancing effect of ureteral occlusion or administration of ethacrynic acid. Acta Physiol Scand 1990; 138: 193–201PubMedCrossRef
28.
Wilkes M, Solomon J, Maita M, et al. Characterization of glomerular thromboxane receptor sites in the rat. Am J Physiol 1989; 256: F1111–6PubMed
29.
Moise KJ, Huhta JC, Sharif DS, et al. Indomethacin in the treatment of premature labor. N Engl J Med 1988; 319: 327–31PubMedCrossRef
30.
Mamapoulos M, Assimakopoulos E, Reece EA, et al. Maternal indomethacin therapy in the treatment of polyhydramnios. Am J Obstet Gynecol 1990; 162: 1225–9
31.
Moise KJ. Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use. Am J Obstet Gynecol 1993; 168: 1350–3PubMed
32.
Gleason CA. Prostaglandins and the developing kidney. Semin Perinatol 1987; 11: 12–21PubMed
33.
Dudley DKL, Hardie MC. Fetal and neonatal effects of indomethacin used as a tocolytic agent. Am J Obstet Gynecol 1985; 151: 181–4PubMed
34.
Niebyl JR, Witter FR. Neonatal outcome after indomethacin treatment for preterm labor. Am J Obstet Gynecol 1986; 155: 747–9PubMed
35.
Morales WJ, Smith SG, Angel JL, et al. ai]Efficacy and safety of indomethacin versus ritodine in the management of preterm labor: a randomized study. Obstet Gynecol 1989; 74: 567–72PubMed
36.
Wurtzel D. Prenatal administration of indomethacin as a tocolytic agent: effect on neonatal renal function. Obstet Gynecol 1990; 76: 689–92PubMed
37.
Itskovitz J, Abramovi H, Brandes JM. Oligohydramnios, meconium and perinatal death concurrent with indomethacin treatment in human pregnancy. J Reprod Med 1980; 24: 137–40PubMed
38.
Jacqz-Aigrin E, Guillonneau M, Boissinot C, et al. Effets maternels et néonatals de l’indomethacine administrée pendant la grossesse. Arch Fr Pediatr 1993; 50: 307–12
39.
Norton ME, Merrill J, Cooper BA, et al. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 1993; 329: 1602–7PubMedCrossRef
40.
Panter KR, Hannah ME, Amankwah KS, et al. The effect of indomethacin tocolysis in preterm labour on perinatal outcome: a randomized placebo-controlled trial. Br J Obstet Gynecol 1999; 106: 467–73CrossRef
41.
Pomeranz A, Korzets Z, Dolfin Z, et al. Acute renal failure in the neonate induced by the administration of indomethacin as a tocolytic agent. Nephrol Dial Transplant 1996; 11: 1139–41PubMedCrossRef
42.
Restaino I, Kaplan BS, Kaplan P, et al. Renal dysgenesis in a monozygotic twin: association with in utero exposure to indomethacin. Am J Med Genet 1991; 39: 252–7PubMedCrossRef
43.
Simeoni U, Messer J, Weisburd P, et al. Neonatal renal dysfunction and intrauterine exposure to prostaglandin synthesis inhibitors. Eur J Pediatr 1989; 148: 371–3PubMedCrossRef
44.
Souter D, Harding J, McCowal L, et al. Antenatal indomethacin — adverse fetal effects confirmed. Aust NZ J Obstet Gynecol 1998; 38: 11–6CrossRef
45.
Van der Heijden BJ, Carlus C, Narcy F, et al. Persistent anuria, neonatal death and renal microcystic lesions after prenatal exposure to indomethacin. Am J Obstet Gynecol 1994; 171 (3): 617–23PubMed
46.
Veersema D, De Jong PA, Van Wijck JAM. Indomethacin and the fetal renal non function syndrome. Eur J Obstet Gynecol Reprod Biol 1983; 16: 113–21PubMedCrossRef
47.
Clyman RI. Medical treatment of patent ductus arteriosus in premature infants. In: Long WA, editor. Fetal and neonatal cardiology. Philadelphia: WB Saunders, 1990: 682–90
48.
Cotton RB, Stahlman MT, Bender HW, et al. Randomized trial of early closure of symptomatic patent ductus arteriosus. J Pediatr 1978; 93: 647–51PubMedCrossRef
49.
Stefano JL, Abbasi S, Pearlman SA, et al. Closure of the ductus arteriosus with indomethacin in ventilated neonates with respiratory distress syndrome: effects on pulmonary compliance and ventilation. Am Rev Respir Dis 1991; 143: 236–9PubMed
50.
Van Overmeire B, Follens I, Hartmann S, et al. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child 1997; 76(3): 179–84
51.
Aranda JV, Varvarigou N, Beharri K, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infants. Acta Pediatr 1997; 86(3): 289–93CrossRef
52.
Betkerur MV, Yeh TF, Miller K, et al. Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus; Pediatrics 1981; 68: 99–102PubMed
53.
Kuo CY. Treatment of patent ductus arteriosus with low-dose indomethacin in very low birth weight neonates with impairment of renal function: report of three cases. J Perinatol Med 1996; 24(6): 657–60CrossRef
54.
Lin YJ, Tsai YJ, Chen JS, et al. Renal effects and urinary excretion of prostaglandin following indomethacin therapy in premature infants with patent ductus arteriosus. Acta Pediatr Sin 1995; 36: 104–7
55.
Ment LR, Oh W, Ehrenkranz RA, et al. Low dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics 1994; 93: 543–50PubMed
56.
Mosca F, Bray M, Lattanzio M, et al. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr 1997; 131(4): 549–54PubMedCrossRef
57.
Ng PC, So KW, Fok TF, et al. Comparing sulindac with indomethacin for closure of ductus arteriosus in preterm infants. J Pediatr Child Health 1997; 33(4): 324–8CrossRef
58.
Patel J, Marks KA, Roberts I, et al. Ibuprofen treatment of patent ductus arteriosus. Lancet 1995; 346: 255PubMedCrossRef
59.
Rennie JM, Doyle J, Cooke RWI. Early administration of indomethacin to preterm infants. Arch Dis Child 1986; 61: 233–8PubMedCrossRef
60.
Van Bel F, Guit GL, Schipper J, et al. Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging. J Pediatr 1991; 118: 621–6PubMedCrossRef
61.
Van Overmeire B, Brus F, Van Acker KJ, et al. Aspirin versus indomethacin treatment of patent ductus arteriosus in preterm infants with respiratory distress syndrome. Pediatr Res 1995; 38(6): 886–91PubMedCrossRef
62.
Varvarigou A, Bardin CL, Beharry K, et al. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA 1996; 275(7): 539–44PubMedCrossRef
63.
Yeh TF, Luken JA, Thaliji A, et al. Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus: a double-blind controlled study. J Pediatr 1981; 98: 137–45PubMedCrossRef
64.
Merritt TA, Harris JP, Roghmann K, et al. Early closure of the patent ductus arteriosus in very low birth weight infants: a controlled trial. J Pediatr 1981; 99: 281–6PubMedCrossRef
65.
Gersony WM, Peckham GJ, Ellison CR, et al. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983; 102: 895–906PubMedCrossRef
66.
Mahony L, Carnero V, Brett C, et al. Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants. N Engl J Med 1982; 306: 506–10PubMedCrossRef
67.
Cotton RB, Haywood JL, Fitzgerald GA. Symptomatic patent ductus arteriosus following prophylactic indomethacin. Biol Neonate 1991; 60: 273–82PubMedCrossRef
68.
Krueger E, Mellander M, Bratton D, et al. Prevention of symptomatic patent ductus arteriosus with a single dose of indomethacin. J Pediatr 1987; 111: 749–54PubMedCrossRef
69.
Laudignon N, Chemtob S, Bard H, et al. Effect of indomethacin on the cerebral blood flow velocity of premature newborns. Biol Neonate 1988; 54: 254–62PubMedCrossRef
70.
Yeh TF, Wilks A, Singh J, et al. Furosemide prevents renal side-effects of indomethacin therapy in preterm infants with persistent ductus arteriosus. J Pediatr 1982; 101: 433–7PubMedCrossRef
71.
Rennie JM, Cooke RWI. Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity. Arch Dis Child 1991; 66: 55–8PubMedCrossRef
72.
Hammerman C, Aramburo MJ. Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus. J Pediatr 1990; 117: 771–6PubMedCrossRef
73.
Fajardo CA, Whyte RK, Steele BT. Effect of dopamine on failure of indomethacin to close the patent ductus arteriosus. J Pediatr 1992; 121: 771–5PubMedCrossRef
74.
Fujiwara T. Closure of PDA with mefenamic acid. In: Robertson B, Van Golde LMG, editors. Pulmonary surfactant. Amsterdam: Elsevier Science Publishers, 1984: 495
75.
Sakhalkar VS, Merchant RH. Therapy of symptomatic patent ductus arteriosus in preterms using mefenamic acid and indomethacin. Indian Pediatr 1992; 29: 313–8PubMed
76.
Coceani F, White E, Bodach E, et al. Age-dependent changes in the response of the lamb ductus arteriosus to oxygen and ibuprofen. Can J Physiol Pharmacol 1979; 57: 825–31PubMedCrossRef
77.
Chemtob S, Beharry K, Rex J, et al. Prostanoids determine the range of cerebral blood flow autoregulation of newborn piglets. Stroke 1990; 21: 777–84PubMedCrossRef
78.
Chemtob S, Beharry K, Barna T, et al. Differences in the effects in the newborn piglet of various nonsteroidal antiinflammatory drugs on cerebral blood flow but not on cerebrovascular prostaglandins. Pediatr Res 1991; 30: 106–11PubMedCrossRef
79.
Malcom DD, Segar JL, Robillard E, et al. Indomethacin compromises hemodynamics during positive-pressure ventilation, independently of prostanoids. J Appl Physiol 1993; 74: 1672–8
80.
Chemtob S, Roy MS, Abran D, et al. Prevention of postasphyxial increase in lipid peroxides and retinal function deterioration in the newborn pig by inhibition of cyclooxygenase activity and free radical generation. Pediatr Res 1993; 33: 336–40PubMed
81.
Aranda JV, Varvarigou N, Beharry K, et al. The effect of early intravenous ibuprofen on renal function in premature newborns [abstract]. Pediatr Res 1994; 37: 361A
82.
Gupta P. Ibuprofen vs indomethacin for treatment of PDA in preterm infants. Indian Pediatr 1998; 35(3): 292–3PubMed
83.
McIntire SC, Rubenstein RC, Gartner JC, et al. Acute flank pain and reversible renal dysfunction associated with nonsteroidal antiinflammatory drug use. Pediatrics 1993; 92: 459–60PubMed
84.
Wattad A, Feehan T, Shepard FM, et al. A unique complication of nonsteroidal antiinflammatory drug use [letter]. Pediatrics 1994; 93: 693PubMed
85.
Lesko SM, Mitchell AA. Renal function after short term ibuprofen use in infants and children. Pediatrics 1997; 100(6): 954–7PubMedCrossRef
86.
Slone D, Shapiro S, Miettinen OS, et al. Drug evaluation after marketing: a policy perspective. Ann Intern Med 1979; 90: 257–61PubMed
87.
Mitchell AA, Lesko SM. When a randomized controlled trial is needed to assess drug safety: the case of pediatric ibuprofen. Drug Saf 1995; 13: 15–24PubMedCrossRef
88.
Al-Harbi NN, Domrongkitchaiporn S, Lirenman DS. Hypocalcemia and hypomagnesemia after ibuprofen overdose. Ann Pharmacother 1997; 31: 432–4PubMed
89.
Kelley MT, Walson PD, Hayes JR, et al. Safety of paracetamol and ibuprofen in febrile children. Drug Invest 1993; 6: 48–55CrossRef
90.
Kim J, Gazarian M, Verjee Z, et al. Acute renal insufficiency in ibuprofen overdose. Pediatr Emerg Care 1995; 11: 107–8PubMedCrossRef
91.
Kovesi TA, Swartz R, MacDonald N. Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis. N Engl J Med 1998; 338(1): 65–6PubMedCrossRef
92.
Lesk SM, Mitchell AA. An assessment of the safety of pediatric ibuprofen: a practitioner-based randomized clinical trial. JAMA 1995; 273: 929–33CrossRef
93.
Moghal NE, Hulton SA, Milford DV. Care in the use of ibuprofen as an antipyretic in children. Clin Nephrol 1998; 49(5): 293–5PubMed
94.
Schaller S, Kaplan BS. Acute nonoliguric renal failure in children associated with nonsteroidal antiinflammatory agents. Pediatr Emerg Care 1998; 14(6): 416–8PubMedCrossRef
95.
Simckes AM, Chen SS, Osorio AV, et al. Ketorolac-induced irreversible renal failure in sickle cell disease: a case report. Pediatr Nephrol 1999; 13: 63–7PubMedCrossRef
96.
Van Biljou G. Reversible renal failure associated with ibuprofen in a child: a case report. S Afr Med J 1989; 76: 34–5
97.
Fanos V, Cataldi L. Antibacterial-induced nephrotoxicity in the newborn. Drug Saf 1999; 20(3): 245–67PubMedCrossRef
98.
Vane JR, Botting RM. Mechanisms of action of anti-inflammatory drugs. In: Vane JR, Botting RM, Botting G editors. Improved non-steroid anti-inflammatory drugs: COX-2 enzyme inhibitors.Dordrecht: Kluwer Academic, 1996: 1–27CrossRef
Metadata
Title
NSAID-Induced Nephrotoxicity from the Fetus to the Child
Authors
Laura Cuzzolin
Monica Dal Cerè
Dr Vassilios Fanos
Publication date
01-01-2001
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 1/2001
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200124010-00002

Other articles of this Issue 1/2001

Drug Safety 1/2001 Go to the issue

Review Article

Bodyweight Gain with Atypical Antipsychotic

Current Opinion

The Role of the Clinical Pharmacologist in the Management of Adverse Drug Reactions

Review Article

Nephrotoxicity and Hepatotoxicity of Histamine H2 Receptor Antagonists

Review Article

Anticancer Drug—Induced Kidney Disorders